NZ738844A - Nucleophilic catalysts for oxime linkage - Google Patents

Nucleophilic catalysts for oxime linkage

Info

Publication number
NZ738844A
NZ738844A NZ738844A NZ73884413A NZ738844A NZ 738844 A NZ738844 A NZ 738844A NZ 738844 A NZ738844 A NZ 738844A NZ 73884413 A NZ73884413 A NZ 73884413A NZ 738844 A NZ738844 A NZ 738844A
Authority
NZ
New Zealand
Prior art keywords
water soluble
soluble polymer
group
active aminooxy
aminooxy group
Prior art date
Application number
NZ738844A
Other languages
English (en)
Inventor
Juergen Siekmann
Stefan Haider
Hanspeter Rottensteiner
Peter Turecek
Original Assignee
Baxalta Inc
Baxalta GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/488,043 external-priority patent/US8809501B2/en
Application filed by Baxalta Inc, Baxalta GmbH filed Critical Baxalta Inc
Publication of NZ738844A publication Critical patent/NZ738844A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Water Supply & Treatment (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NZ738844A 2012-05-16 2013-05-16 Nucleophilic catalysts for oxime linkage NZ738844A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261647814P 2012-05-16 2012-05-16
US13/488,043 US8809501B2 (en) 2009-07-27 2012-06-04 Nucleophilic catalysts for oxime linkage
NZ724828A NZ724828A (en) 2012-05-16 2013-05-16 Nucleophilic catalysts for oxime linkage

Publications (1)

Publication Number Publication Date
NZ738844A true NZ738844A (en) 2018-12-21

Family

ID=48579473

Family Applications (4)

Application Number Title Priority Date Filing Date
NZ738844A NZ738844A (en) 2012-05-16 2013-05-16 Nucleophilic catalysts for oxime linkage
NZ724828A NZ724828A (en) 2012-05-16 2013-05-16 Nucleophilic catalysts for oxime linkage
NZ701945A NZ701945A (en) 2012-05-16 2013-05-16 Nucleophilic catalysts for oxime linkage
NZ738846A NZ738846A (en) 2012-05-16 2013-05-16 Nucleophilic catalysts for oxime linkage

Family Applications After (3)

Application Number Title Priority Date Filing Date
NZ724828A NZ724828A (en) 2012-05-16 2013-05-16 Nucleophilic catalysts for oxime linkage
NZ701945A NZ701945A (en) 2012-05-16 2013-05-16 Nucleophilic catalysts for oxime linkage
NZ738846A NZ738846A (en) 2012-05-16 2013-05-16 Nucleophilic catalysts for oxime linkage

Country Status (12)

Country Link
EP (3) EP2849794A1 (https=)
JP (5) JP6195611B2 (https=)
KR (4) KR102110622B1 (https=)
CN (2) CN109620963B (https=)
AU (1) AU2013204754C1 (https=)
BR (1) BR112014028636B1 (https=)
CA (1) CA2873756C (https=)
EA (2) EA035506B1 (https=)
MX (1) MX360594B (https=)
NZ (4) NZ738844A (https=)
SG (3) SG10201911328QA (https=)
WO (2) WO2013173543A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013204754C1 (en) * 2012-05-16 2018-10-11 Takeda Pharmaceutical Company Limited Nucleophilic Catalysts for Oxime Linkage
CN109963579A (zh) * 2016-11-14 2019-07-02 诺华股份有限公司 用于治疗软骨损伤和关节炎的方法和组合物
JP7002036B2 (ja) * 2016-11-17 2022-01-20 パナソニックＩｐマネジメント株式会社 膜電極接合体および固体酸化物形燃料電池
WO2018112669A1 (en) * 2016-12-23 2018-06-28 Realist Pharma, Inc. Ganglioside carbohydrate structures and uses thereof
CN108503901B (zh) * 2018-04-17 2020-07-07 哈尔滨工业大学 一种抗菌普鲁兰多糖/壳聚糖复合食品包装膜的制备方法
US11845989B2 (en) 2019-01-23 2023-12-19 Regeneron Pharmaceuticals, Inc. Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors
JP2022523301A (ja) 2019-01-23 2022-04-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッド アンジオポエチン様７（ａｎｇｐｔｌ７）阻害剤による眼疾患の治療
WO2022182768A1 (en) 2021-02-26 2022-09-01 Regeneron Pharmaceuticals, Inc. Treatment of inflammation with glucocorticoids and angiopoietin-like 7 (angptl7) inhibitors
JPWO2023171638A1 (https=) 2022-03-07 2023-09-14
WO2025133203A1 (en) * 2023-12-22 2025-06-26 Pam Theragnostics Gmbh Compounds and methods for a long-lasting pam

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54113492A (en) 1978-02-24 1979-09-05 Sanyo Chem Ind Ltd Preparation of glucoprotein derivative
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US5250421A (en) 1986-01-03 1993-10-05 Genetics Institute, Inc. Method for producing factor VIII:C-type proteins
US5198349A (en) 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
JPH0387173A (ja) 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
US5846951A (en) 1991-06-06 1998-12-08 The School Of Pharmacy, University Of London Pharmaceutical compositions
DE69329795T2 (de) 1992-10-02 2001-07-05 Genetics Institute, Inc. Zusammensetzung, welche den koagulationsfaktor viii beinhaltet; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator
NZ250375A (en) * 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
WO1994028024A1 (en) * 1993-06-01 1994-12-08 Enzon, Inc. Carbohydrate-modified polymer conjugates with erythropoietic activity
US5621039A (en) 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
WO1996040662A2 (en) 1995-06-07 1996-12-19 Cellpro, Incorporated Aminooxy-containing linker compounds and their application in conjugates
WO1999003496A1 (en) 1997-07-21 1999-01-28 The University Of North Carolina At Chapel Hill Factor ix antihemophilic factor with increased clotting activity
US7074878B1 (en) 1999-12-10 2006-07-11 Harris J Milton Hydrolytically degradable polymers and hydrogels made therefrom
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
AU2001258536A1 (en) 2000-05-16 2001-11-26 Lipoxen Technologies Limited Derivatisation of proteins in aqueous solution
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
AU2002352524B2 (en) 2001-11-07 2007-10-04 Nektar Therapeutics Branched polymers and their conjugates
BR0314106A (pt) 2002-09-11 2005-07-19 Fresenius Kabi De Gmbh Polipeptìdeos hasilados, especialmente eritropoietina hasilada
EP1681303B1 (en) 2002-09-11 2013-09-04 Fresenius Kabi Deutschland GmbH HASylated polypeptides, especially HASylated erythropoietin
CA2521784C (en) 2003-04-08 2012-03-27 Yeda Research And Development Co. Ltd. Reversible pegylated drugs
EP2055189A1 (en) 2003-04-09 2009-05-06 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
EP1653991A2 (en) * 2003-08-08 2006-05-10 Fresenius Kabi Deutschland GmbH Conjugates of a polymer and a protein linked by an oxime linking group
WO2005016974A1 (en) 2003-08-12 2005-02-24 Lipoxen Technologies Limited Sialic acid derivatives for protein derivatisation and conjugation
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
KR101237884B1 (ko) 2003-12-03 2013-02-27 바이오제너릭스 에이지 글리코 peg화 과립구 콜로니 자극인자
WO2006016168A2 (en) 2004-08-12 2006-02-16 Lipoxen Technologies Limited Sialic acid derivatives
WO2006031811A2 (en) 2004-09-10 2006-03-23 Neose Technologies, Inc. Glycopegylated interferon alpha
CA2591852A1 (en) 2004-12-27 2006-07-06 Baxter International Inc. Polymer-von willebrand factor-conjugates
BRPI0611872B8 (pt) 2005-06-16 2021-05-25 Nektar Therapeutics reagente polimérico, conjugado, método para preparação de um conjugado e composição farmacêutica
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
WO2008025856A2 (en) 2006-09-01 2008-03-06 Novo Nordisk Health Care Ag Modified glycoproteins
CA2670618C (en) * 2006-12-15 2016-10-04 Baxter International Inc. Factor viia- (poly) sialic acid conjugate having prolonged in vivo half-life
GB0908393D0 (en) * 2009-05-15 2009-06-24 Almac Sciences Scotland Ltd Labelling method
CN102497884A (zh) * 2009-07-27 2012-06-13 巴克斯特国际公司 凝血蛋白缀合物
KR101912335B1 (ko) * 2009-07-27 2018-10-26 리폭센 테크놀로지즈 리미티드 비혈액 응고 단백질의 글리코폴리시알화
DK2598172T3 (da) * 2010-07-30 2019-07-01 Baxalta GmbH Nukleofile katalysatorer til oximforbindelse
KR101560541B1 (ko) * 2012-04-13 2015-10-19 아우토리브 디벨롭먼트 아베 에어백 모듈과 스티어링 휠의 조립체
AU2013204754C1 (en) * 2012-05-16 2018-10-11 Takeda Pharmaceutical Company Limited Nucleophilic Catalysts for Oxime Linkage

Also Published As

Publication number Publication date
JP2017145260A (ja) 2017-08-24
EA028186B1 (ru) 2017-10-31
KR20210099187A (ko) 2021-08-11
JP2022034075A (ja) 2022-03-02
JP7304402B2 (ja) 2023-07-06
AU2013204754C1 (en) 2018-10-11
JP7014844B2 (ja) 2022-02-01
EA201492115A1 (ru) 2015-05-29
CN104487095A (zh) 2015-04-01
SG10201911328QA (en) 2020-01-30
MX2014013919A (es) 2015-06-05
EP4019049A1 (en) 2022-06-29
KR102287040B1 (ko) 2021-08-09
KR20150008192A (ko) 2015-01-21
KR102110622B1 (ko) 2020-05-14
JP2020111599A (ja) 2020-07-27
SG10201701780RA (en) 2017-04-27
BR112014028636A2 (https=) 2017-08-15
EP2849795A1 (en) 2015-03-25
BR112014028636B1 (pt) 2022-09-20
KR20210041629A (ko) 2021-04-15
AU2013204754B2 (en) 2015-11-05
JP2019089810A (ja) 2019-06-13
JP2015520163A (ja) 2015-07-16
CN104487095B (zh) 2018-12-07
HK1209024A1 (en) 2016-03-24
NZ701945A (en) 2016-10-28
WO2013173543A1 (en) 2013-11-21
NZ738846A (en) 2019-05-31
MX360594B (es) 2018-11-09
SG11201407597XA (en) 2014-12-30
EA028186B9 (ru) 2018-05-31
KR20200053636A (ko) 2020-05-18
JP6560712B2 (ja) 2019-08-14
CA2873756A1 (en) 2013-11-21
WO2013173557A1 (en) 2013-11-21
KR102237306B1 (ko) 2021-04-08
JP6711935B2 (ja) 2020-06-17
KR102326360B1 (ko) 2021-11-15
EP2849795B1 (en) 2022-04-06
EP2849794A1 (en) 2015-03-25
JP6195611B2 (ja) 2017-09-13
CN109620963A (zh) 2019-04-16
NZ724828A (en) 2018-02-23
CN109620963B (zh) 2022-10-28
EA201790935A1 (ru) 2017-12-29
EA035506B1 (ru) 2020-06-25
CA2873756C (en) 2022-08-16

Similar Documents

Publication Publication Date Title
NZ738844A (en) Nucleophilic catalysts for oxime linkage
Stern et al. Hyaluronidases: their genomics, structures, and mechanisms of action
Mero et al. Hyaluronic acid bioconjugates for the delivery of bioactive molecules
CN103613686B (zh) 巯基化透明质酸的制备方法及其应用
Tiera et al. Synthesis and characterization of phosphorylcholine-substituted chitosans soluble in physiological pH conditions
Bo et al. Sulfation and biological activities of konjac glucomannan
Masuko et al. Thiolation of chitosan. Attachment of proteins via thioether formation
JP5812537B2 (ja) アミノ糖含有グルカン、その製造法および利用
US11098168B2 (en) Method for preparing cross-linked hyaluronic acid gel and cross-linked hyaluronic acid gel prepared by the same
JP6649892B2 (ja) ヒアルロン酸オリゴマーの複合体又はその塩，その調製法及びその使用
WO2002018448A3 (en) Percarboxylated polysaccharides, and a process for their preparation
Wilson et al. 1H NMR spectroscopic studies establish that heparanase is a retaining glycosidase
DeAngelis Heparosan, a promising ‘naturally good’polymeric conjugating vehicle for delivery of injectable therapeutics
Wang et al. Characterization and comparison of carboxymethylation and TEMPO-mediated oxidation for polysaccharides modification
Azeez et al. Recent developments on the application of carbohydrate polymers
MX373250B (es) Conjugación de polisacáridos capsulares de tipo 5 y de tipo 8 de staphylococcus aureus.
CN106866998A (zh) 一种壳聚糖季铵盐/羧甲基纤维素超吸水凝胶及其制备方法和应用
Silva et al. Polysaccharides from exudate gums of plants and interactions with the intestinal microbiota: A review of vegetal biopolymers and prediction of their prebiotic potential
KR101170033B1 (ko) 알돈산 에스테르, 알돈산 에스테르를 포함하는 고형물과 용액, 알돈산 에스테르를 제조하는 방법, 약제 활성 성분 및 약제 활성 성분 제조 방법
WO2021098098A1 (zh) 巯基改性透明质酸及其制备方法和用途
CN105294870B (zh) 一种螺旋藻多糖及其制备方法
CN100390203C (zh) 在外科或治疗性治疗哺乳动物的方法中或在诊断方法中使用的高支化支链淀粉
Joseph et al. [Retracted] Conversion of Aquaculture Waste into Biomedical Wealth: Chitin and Chitosan Journey
Ming-Jiang et al. Structural analysis of water-soluble polysaccharide PIP1 extracted from the cultured mycelium of Phellinus igniarius
Kurita et al. Synthesis and macrophage activation of lentinan-mimic branched amino polysaccharides: curdlans having N-Acetyl-d-glucosamine branches

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 MAY 2020 BY ANAQUA SERVICES

Effective date: 20190418

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 MAY 2021 BY ANAQUA SERVICES

Effective date: 20200424

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 MAY 2022 BY ANAQUA SERVICES

Effective date: 20210421

ASS Change of ownership

Owner name: TAKEDA PHARMACEUTICAL COMPANY, JP

Effective date: 20210621

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 MAY 2023 BY ANAQUA SERVICES

Effective date: 20220423

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 MAY 2024 BY ANAQUA SERVICES

Effective date: 20230420

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 MAY 2025 BY ANAQUA SERVICES

Effective date: 20240418

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 MAY 2026 BY ANAQUA SERVICES

Effective date: 20250423